It's been another remarkable year for global biopharma, and the Scrip team is delighted to reveal the companies, teams and individuals who have made the shortlist for the 22nd annual Scrip Awards.
Congratulations to everyone shortlisted you represent the very best of an industry that continues to innovate, take bold risks and, above all, improve patients' lives around the world.
Made the shortlist? Here's what happens next.
If you've been shortlisted, you qualify for a specially discounted table at the awards evening so you can celebrate alongside the leading names in pharma at the black-tie gala dinner and ceremony at Raffles London at the OWO on Wednesday, 2 December 2026, with headline sponsor ICON.
Whether you're on the shortlist or simply want to be part of a night that celebrates excellence across the global biopharma landscape, we'd love to see you there. To book your seat or table, or if you have any questions about the ceremony, reach out to the Scrip Awards team at natalia.kay@citeline.com.
The Shortlist
View the shortlist →Ceremony date
Wednesday, 2 December 2026
Drinks reception from 6.30pm
Location
Raffles London at the OWO
57 Whitehall, London SW1A 2BX
Book your place
Book your place →Click here to see our full entry guide for more information.
For any enquiries about the Scrip Awards 2026, please contact us at natalia.kay@citeline.com.
The Best New Drug Award recognizes excellence in pharmaceutical development. Launching innovative new products is the most important function of the industry, and a successful new drug launch marks the culmination of years of risky and expensive R&D. In this category, the judges will be looking for the small-molecule or biological product that was approved in its first market worldwide during the qualifying period that represents the best therapeutic advance in its area.
FINALISTS
This Award seeks to recognize success in a clinical trial of a new drug product (biological or chemical) that is expected to lead to an advance in healthcare. This might include the first demonstration of a clear clinical effect for a new drug in an area of unmet medical need, a pivotal study of a new drug with a breakthrough mechanism of action, or a major study of a potential new or expanded indication for an already marketed product. The product involved need not yet be approved, but the judges will be looking for innovation, clear proof of benefit and potential commercial reward. To be eligible, the study in question must have been presented for peer review at a major medical meeting or been published in a scientific journal between 1 July 2025 – 30 June 2026.
FINALISTS
FINALISTS
Deals are vital both in helping to keep pharma’s pipelines replenished and in generating income for smaller firms or exits for investors. Deals considered here are those that involve the licensing of a particular drug, project or group of closely related drugs/projects from one company to another for further development and/or marketing, or M&A deals centred around a product or group of related products. Please note, it does not include more involved partnerships between companies to explore particular therapeutic strategies (see Criteria for the Best Partnership Alliance)
FINALISTS
Scrip’s Best Partnership Alliance Award recognizes the importance of pharmaceutical and/or biotech companies working together to develop new medicines from the earliest stages. This category seeks to reward innovative partnerships between companies in which they share the risks and rewards inherent in exploring novel therapeutic strategies and developing new drugs.
FINALISTS
The biotech industry’s entrepreneurial spirit and cutting-edge science have transformed the research and development of medicines in the past few decades. This Award honours outstanding achievement by biotech companies over the qualifying 12 months.
FINALISTS
The Awards for the Best Contract Research Organization acknowledge the critical role that CROs play in drug development. Clinical outsourcing is vital as the pharmaceutical industry seeks to benefit more and more from these specialist companies’ experience in handling all aspects of clinical trials. The Awards for CROs are split into two sister categories to separate the larger full-service providers from those smaller CROs that provide specialist services to their clients.
FINALISTS
The Awards for the Best Contract Research Organization acknowledge the critical role that CROs play in drug development. Clinical outsourcing is vital as the pharmaceutical industry seeks to benefit more and more from these specialist companies’ experience in handling all aspects of clinical trials. The Awards for CROs are split into two sister categories to separate the larger full-service providers from those smaller CROs that provide specialist services to their clients.
FINALISTS
This new Scrip Award seeks to recognize early clinical advances in oncology made by small biopharma companies. The great strides seen in cancer therapies in recent years often had their genesis in the labs of specialist firms. We are looking to reward companies that are exploiting new knowledge in cancer cell biology and the tumor microenvironment to forge new paths to tackle the disease, for instance by developing novel therapeutic strategies in immuno-oncology, gene and cell therapies and new targeted agents.
This category is aimed at clinical-stage oncology firms pioneering new approaches in the treatment of cancer that have shown proof of concept in early (Phase I or II) clinical trials and have candidates moving forward in the development pathway.
FINALISTS
Scrip’s Business Development Team of the Year Award will honor the achievements of business development teams whether they are from a pharma or biotech company or a cross-company team responsible for a specific deal or collaborative project which took place between 1 July 2025 – 30 June 2026.
FINALISTS
This Award is designed to acknowledge the numerous ways in which pharma and biotech companies give back to the wider community. This could include outreach within a local community, with a charity or patient advocacy group, or alongside an NGO or humanitarian organization.
FINALISTS
This new category seeks to reward AI innovation in tasks such as improving clinical trial design, site selection and recruitment, identifying responders, reducing protocol burden and improving operational performance.
FINALISTS
This new category seeks to reward AI innovation in tasks such as identifying targets, validating biology, discovering candidates, optimizing molecules and improving preclinical decision making.
FINALISTS
The Pharma Company of the Year Award honors outstanding achievements by pharmaceutical companies over the qualifying 12 months between 1 July 2025 – 30 June 2026.
This special Award is chosen by Scrip’s senior editorial team, based on a variety of key metrics. The winner will be announced on the night of the Scrip Awards.
The winner of this Award will be an exceptional individual with a consistent history of service, above and beyond the call of duty, throughout their career. This prestigious international Award will go to someone who has had a distinguished career in the biotech or pharmaceutical arena, primarily within industry.
ICON plc is a world-leading clinical research organisation. Offering deep operational and medical expertise we accelerate innovation, driving emerging therapies forward to improve patient outcomes. From molecule to medicine, we deliver integrated consulting, clinical development, commercialisation and post-marketing solutions to pharmaceutical, biotechnology, medical device, government and public health organisations worldwide.
Our focus is on addressing the full spectrum of clinical development challenges, not just point-of-service delivery. An extensive services portfolio and technology capabilities, combined with flexible delivery and models, allow us to reduce development time and costs for clients.
For further information about ICON, visit: www.iconplc.com.
The Scrip Awards are a highlight in my annual calendar, bringing together an incredible calibre of people from across pharma and biotech.
Sponsoring the awards provides ICON with a high-profile presence, creating brand visibility, and supporting connections and conversation with a senior clinical development community focused driving medical progress and innovation.
Our industry matters to human health and saving lives. These awards matter to the industry.
JUL 11, 2025
Headline sponsor
DEC 04, 2024
Headline sponsor
JUL 07, 2023
Headline sponsor